Vardenafil ODT (Each)

Often prescribed for erectile dysfunction (ED), vardenafil is in the phosphodiesterase type 5 (PDE5) inhibitor drug class. Like sildenafil and tadalafil, this is a selective phosphodiesterase (PDE) type 5 inhibitor. Unlike some ED-treating drugs (e.g., alprostadil), this class of medicines does not impede prostaglandins. This causes less visual negative consequences such as those described in sildenafiltreated patients. One benefit of vardenafil is that it reaches peak plasma concentration sooner than sildenafil and tadalafil, hence providing for a faster onset of action. Efficacy in an evaluation of 580 patients found that 80% of males had improved erections and greater capacity to finish sexual intercourse with ejaculation. Treatment of diabetics and those with radical prostectomy is also seen to be shown. Oral PDE5 inhibitors, often used firstline according ED treatment guidelines, The FDA authorized vardenafil in August 2003 to treat erectile dysfunction; an orally disintegrating tablet was approved by the FDA in June 2010.

Selective inhibitor of cyclic guanosine monophosphate (cGMP)specific phosphodiesterase type 5 (PDE5), vardenafil is. Following this, nitric oxide activates the enzyme guanylate cyclase, which increases levels of cGMP. Smooth muscle relaxation in the corpus results from cyclic guanosine monophosphate. Cavernosum hence enables blood flow; the precise process by which cGMP causes smooth muscle relaxation has not been identified. Degradation of cGMP in the corpus cavernosum is caused by phosphodiesterase type 5. By blocking PDE5, vardenafil increases corpus cavernosum cGMP levels and thus enhances NO’s effect. Compared to PDE6, an enzyme present in the retina involved in phototransduction, vardenafil exhibits more selectivity for PDE5. Sildenafil, another PDE inhibitor, has a Reduced selectivity for PDE5 versus PDE6 is linked with abnormalities affecting color vision at higher doses or plasma drug levels.

Lung tissue and esophageal smooth muscle have a lot of phosphodiesterase type 5 as well. Inhibition of PDE5 in lung tissue causes pulmonary vasodilation that could be helpful in managing pulmonary hypertension. In some motor disorders affecting the esophagus, including diffuse spasm, nutcracker esophagus, and hypertensive LES, these effects could be helpful. Still, lowering the LES tone can aggravate the symptoms of gastroesophageal reflux disease (GERD). One of the more often occurring side effects related with PDE inhibitor treatment is dyspepsia.

Before starting vardenafil, it’s very important to share your full medical history with your healthcare provider. Certain health conditions can affect whether this medication is safe or suitable for you. Be sure to tell your doctor if you have any bleeding disorders, eye or vision problems (including a rare inherited condition called retinitis pigmentosa), or any penile abnormalities such as Peyronie’s disease or a history of priapism, which is a painful and prolonged erection. Heart-related issues are also important to mention, including heart disease, angina, previous heart attacks, irregular heartbeats, or other heart problems. Additionally, if you have high or low blood pressure, blood diseases like sickle cell anemia or leukemia, a history of stomach bleeding, kidney or liver disease, or a stroke, your doctor needs to know. Also inform them if you have had any unusual or allergic reactions to vardenafil, other medicines, foods, dyes, or preservatives. Women who are pregnant, trying to get pregnant, or breastfeeding should not use vardenafil.

It is also not safe to use vardenafil together with nitrate or nitrite medications, which are often prescribed for chest pain or heart problems. This includes any form of nitrates, even if taken occasionally. If you are on nitrate therapy, you should not take vardenafil at all. Also, it’s not known how long you should wait after taking vardenafil before it’s safe to use nitrates, so caution is essential.

People with severe liver disease or those on dialysis for kidney failure should avoid vardenafil because its safety in these groups hasn’t been established. Mild liver or kidney issues usually don’t require dose changes. Elderly patients (65 years and older) tend to have higher levels of the drug in their system, so a lower starting dose is recommended. Older adults may also have kidney or liver problems that increase drug levels, raising the risk of side effects.

Because sexual activity can put stress on the heart, your doctor will carefully evaluate your heart health before prescribing vardenafil. Use caution if you have had a recent heart attack, stroke, or serious heart rhythm problems, or if you have very low or very high blood pressure. Vardenafil can affect the heart’s electrical activity, so it should be avoided in people with certain heart rhythm disorders or those taking medications that affect heart rhythm. If you have conditions like heart failure, coronary artery disease, or low blood volume, your doctor will carefully consider the risks.

Vardenafil can cause prolonged erections lasting more than four hours, which can damage the penis if not treated promptly. Use caution if you have penile structural problems or blood disorders that increase the risk of priapism, such as sickle cell disease, leukemia, or a history of priapism.

Safe sex practices should still be followed, and your healthcare provider can offer counseling on protective measures, including HIV prevention.

If you have pre-existing vision problems, be aware that sudden vision loss has been reported with drugs like vardenafil. This is due to a rare condition where blood flow to the optic nerve is blocked, potentially causing permanent vision loss. People with inherited retinal diseases like retinitis pigmentosa should avoid vardenafil until more information is available.

Vardenafil is not approved for use in women, pregnant or breastfeeding individuals, or children. Its safety during pregnancy and breastfeeding is not established, and it is not intended for use in these groups.

If you have gastroesophageal reflux disease (GERD) or hiatal hernia, vardenafil may worsen symptoms by relaxing the lower esophageal sphincter, which can increase acid reflux.

For patients with bleeding disorders or active stomach ulcers, vardenafil should be used only after careful consideration, as its effects in these conditions are not well studied. While vardenafil itself does not increase bleeding time, caution is advised.

If you notice any hearing changes, stop the medication and seek medical help immediately.

The orally disintegrating form of vardenafil contains aspartame, which includes phenylalanine. This can be harmful to people with phenylketonuria, a rare genetic disorder. It also contains sorbitol, which should be avoided by those with hereditary fructose intolerance.

Special Considerations for Certain Groups:

Liver Impairment: People with mild liver problems may have slightly higher levels of vardenafil in their blood, but usually no dose adjustment is needed. Vardenafil has not been studied in people with severe liver disease, so it is not recommended for them.

Kidney Impairment: Mild to moderate kidney problems do not usually require dose changes. However, vardenafil has not been studied in patients on dialysis, so caution is advised.

Elderly Patients: Older adults tend to have higher blood levels of vardenafil, so starting with a lower dose is recommended. Clinical studies have shown that vardenafil is generally safe and effective in elderly patients when dosed appropriately.

Before taking vardenafil, it’s very important to tell your healthcare provider about all the medications you are currently using, including prescription drugs, over-the-counter medicines, herbal supplements, and vitamins. This is because vardenafil can interact with many other medications, which may increase the risk of side effects or reduce how well the drugs work.

Medications You Should NOT Take with Vardenafil

There are certain medicines that should never be taken together with vardenafil because of serious risks:

Nitrates and Nitrites: These include drugs like nitroglycerin, isosorbide dinitrate, isosorbide mononitrate, amyl nitrite, and nitroprusside. This combination is strictly contraindicated.

Certain Heart Medications: Bepridil, dronedarone, dofetilide, and other drugs used to treat irregular heartbeats should not be combined with vardenafil because of the risk of serious heart rhythm problems.

Some Antifungal Medications: Drugs like fluconazole, itraconazole, ketoconazole, posaconazole, and voriconazole can increase vardenafil levels in your body, raising the chance of side effects.

Other Erectile Dysfunction Drugs: Avoid using vardenafil with other PDE5 inhibitors such as sildenafil, tadalafil, or avanafil.

Cisapride and Droperidol: These medications can also cause serious heart rhythm issues when taken with vardenafil.

Medications That May Interact with Vardenafil

Some drugs may interact with vardenafil and require caution or dose adjustments:

HIV/AIDS Medications: Certain antiviral drugs, especially ritonavir and saquinavir (often used with ritonavir), can greatly increase vardenafil levels, increasing side effects like low blood pressure, dizziness, vision changes, or prolonged erections. If you are on these medications, your doctor will likely prescribe a much lower dose of vardenafil and monitor you closely.

Dose adjustments and careful monitoring are needed.

Blood Pressure Medications: Alpha-blockers (like terazosin and tamsulosin) and other antihypertensives can lower blood pressure. When combined with vardenafil, there is a risk of symptomatic low blood pressure (hypotension). Your doctor will ensure you are stable on these medications before starting vardenafil and may start with a low dose.

Other Drugs That Affect Heart Rhythm: Vardenafil can prolong the QT interval on an ECG, which is a measure of heart rhythm. Combining it with other drugs that also prolong the QT interval can increase the risk of dangerous arrhythmias. Your doctor will review your medications carefully to avoid this risk.

CYP3A4 Inhibitors: Vardenafil is broken down in the body by an enzyme called CYP3A4. Drugs that block this enzyme, such as ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, and grapefruit juice, can increase vardenafil levels, raising the chance of side effects. If you need to take these drugs together, your doctor will likely lower your vardenafil dose or avoid certain forms like the orally disintegrating tablets, which increase drug exposure.

CYP3A4 Inducers: Some drugs, like rifampin, phenytoin, carbamazepine, and others, speed up the breakdown of vardenafil, which may reduce its effectiveness.

Important Notes About Specific Interactions

Taking vardenafil with nitrates is dangerous and should be avoided completely.

Combining vardenafil with alpha-blockers requires caution. Your doctor will start with low doses and monitor your blood pressure closely.

Some antifungal medications like posaconazole and fluconazole are contraindicated with vardenafil because they can cause life-threatening heart rhythm problems.

Certain HIV medications, especially ritonavir and saquinavir, can dramatically increase vardenafil levels. Dose adjustments and close monitoring are essential.

Grapefruit juice can increase vardenafil levels and should be avoided, especially with the orally disintegrating tablets.

If you are taking medications that prolong the QT interval, your doctor will carefully weigh the risks before prescribing vardenafil.

What You Should Do

Inform your doctor if you smoke, drink alcohol, or use recreational drugs, as these can also affect how vardenafil works or increase side effects.

If you experience symptoms like dizziness, fainting, chest pain, irregular heartbeat, or vision changes while taking vardenafil, seek medical attention immediately.

Vardenafil is a medication used to treat erectile dysfunction, and like all medicines, it can cause side effects. Some side effects are serious and need immediate medical attention, while others are milder and may go away on their own. It’s important to know which symptoms to watch for and when to contact your doctor.

Serious Side Effects to Report Immediately

If you experience any of the following, stop taking vardenafil and seek medical help right away:

Allergic reactions such as skin rash, itching, hives, or swelling of the face, lips, or tongue
Difficulty breathing or chest tightness
Changes in hearing, like sudden hearing loss or ringing in the ears
Chest pain or a fast, irregular heartbeat
Prolonged or painful erections lasting more than 4 hours (priapism)
Seizures or convulsions
These symptoms could indicate serious health problems and require urgent care.

Common Side Effects That Usually Don’t Need Medical Attention

Some side effects are more common but tend to be mild or temporary. You should tell your doctor if these continue or bother you:

Headache
Dizziness
Indigestion or upset stomach
Muscle aches or back pain
Nausea
Stuffy or runny nose
Flushing happens in about 7 to 11% of people taking vardenafil, and it tends to increase with higher doses.

Less Common Side Effects

Some side effects occur in fewer than 2% of patients but are still important to be aware of:

Neurological symptoms such as weakness, numbness, sleep problems, memory issues, or seizures
Gastrointestinal problems including abdominal pain, diarrhea, vomiting, dry mouth, and acid reflux
Muscle cramps, neck pain, or increased muscle tone
Cardiovascular effects like chest pain, changes in blood pressure, palpitations, or fainting
Respiratory issues such as nasal congestion, sinus infections, or flu-like symptoms
Ejaculation problems or nosebleeds
Visual disturbances including changes in color vision, blurred vision, eye pain, or light sensitivity
Vision and Hearing Concerns

Vardenafil can affect vision because it influences certain enzymes in the retina. Some people have reported temporary changes in color perception, especially blue and green hues, usually around the time the medication is at its peak level in the blood. Rarely, more serious eye problems like sudden vision loss or optic nerve damage (non-arteritic anterior ischemic optic neuropathy, or NAION) have been reported. These serious eye issues often happen in people with existing risk factors such as diabetes, high blood pressure, heart disease, or certain anatomical features of the eye.

Sometimes these hearing changes come with dizziness or vertigo. If you notice any sudden changes in your hearing, contact your doctor immediately.

Effects on Heart and Blood Pressure

These effects typically occur within 1 to 4 hours after taking the medication. Because of this, vardenafil may add to the blood pressure-lowering effects of other medications, so your doctor will monitor you closely if you are on antihypertensive drugs.

Rarely, serious heart-related side effects like chest pain, heart attack, or abnormal heart rhythms have been reported. If you experience chest pain or irregular heartbeat, seek medical attention immediately.

Other Possible Side Effects

Respiratory symptoms such as nasal congestion, sinusitis, or flu-like symptoms are relatively common.
Muscle and joint pain, including back pain and neck pain, have been reported.
Some patients experience sleep disturbances like insomnia or drowsiness.
Changes in laboratory tests, such as elevated liver enzymes or muscle enzymes, have been seen but are uncommon.
Important Precautions

If you have a history of allergic reactions to vardenafil or similar drugs, do not take it.
People with certain heart conditions, low blood pressure, or those taking medications that affect heart rhythm should use vardenafil cautiously.
Prolonged erections lasting more than 4 hours require emergency medical treatment to prevent permanent damage.
Vardenafil does not protect against sexually transmitted infections; safe sex practices are still necessary.
If you have pre-existing vision or hearing problems, discuss these with your doctor before starting vardenafil.
Summary

While many people tolerate vardenafil well, it can cause side effects ranging from mild to serious. Common side effects include headache, flushing, and indigestion, which often improve over time. Serious side effects like allergic reactions, chest pain, sudden vision or hearing loss, and prolonged erections require immediate medical attention. Always communicate openly with your healthcare provider about any side effects you experience, and never hesitate to seek emergency care if you have symptoms that concern you.

Women are not advised to take vardenafil. Vardenafil falls under FDA pregnancy risk category B. There are no good and well-controlled human studies of vardenafil in pregnancy.

Though vardenafil is known to be excreted into the milk of lactating animals, it is unknown if it is excreted into human breastmilk. rats at densities almost ten times higher than those seen in the blood.

Store this medication at 68°F to 77°F (20°C to 25°C) and away from heat, moisture and light. Keep all medicine out of the reach of children. Throw away any unused medicine after the beyond use date. Do not flush unused medications or pour down a sink or drain.

1. Montague DK, Jarow JP, Broderick GA, et al. Chapter 1: The management of erectile dysfunction: an AUA update. J Urol 2005;174:230-9.
2. Levitra (vardenafil) package insert. Kenilworth, NJ: Schering-Plough; 2007 Mar.
3. Staxyn (vardenafil orally disintegrating tablets) package insert. Whitehouse Station, NJ: Schering-Plough; 2010 Jun.
4. Thadani U, Smith W, Nash S, et al. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am C
5. Roden, DM. Drug-induced prolongation of the QT interval. New Engl J Med 2004;350:1013-22.
6. Crouch MA, Limon L, Cassano AT. Clinical relevance and management of drug-related QT interval prolongation. Pharmacotherapy 2003;23:881-908.
7. van Noord C, Eijgelsheim M, Stricker BH. Drug- and non-drug-associated QT interval prolongation. Br J Clin Pharmacol 2010;70(1):16-23.
8. Benoit SR, Mendelsohn AB, Nourjah P, et al. Risk factors for prolonged QTc among US adults: Third National Health and Nutrition Examination Survey. Eur J Cardiovasc Prev Rehabil 2005;12(4):363-368.
9. Koide T, Ozeki K, Kaihara S, et al. Etiology of QT prolongation and T wave changes in chronic alcoholism. Jpn Heart J 1981;22:151-166.
10. Galli-Tsinopoulou A, Chatzidimitriou A, Kyrgios I, et al. Children and adolescents with type 1 diabetes mellitus have a sixfold greater risk for prolonged QTc interval. J Pediatr Endocrinol Metab 2014;27:237-243.
11. Burnett AL, Bivalacqua TJ. Priapism: current principles and practice. Urol Clin N Am 2007;34:631-642.
12. Bortolotti M, Mari C, Giovannini M, et al. Effects of sildenafil on esophageal motility of normal subjects. Dig Dis Sci 2001;46:2301-2306.
13. Levitra® (vardenafil) package insert. Kenilworth, NJ: Schering-Plough; 2007 Mar.
14. Cialis (tadalafil) package insert. Indianapolis, IN: Lilly ICOS, LLC; 2011 Oct.
15. Freedman RA, Anderson KP, Green LS, et al. Effect of erythromycin on ventricular arrhythmias and ventricular repolarization in idiopathic long QT syndrome. Am J Cardiol 1987;59:168-9.
16. CredibleMeds. Drugs to avoid in congenital long QT. Available on the World Wide Web at http://www.crediblemeds.org.– LinkOpens in New Tab
17. Ery-tab (erythromycin delayed-release tablets) package insert. Atlanta, GA: Arbor Pharmaceuticals, Inc.; 2013 July.
18. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/ContentFiles/AdultandAdo– LinkOpens in New Tab
19. Norvir® (Ritonavir) package insert. Chicago, IL: Abbott Laboratories; 2008 Aug.
20. Biaxin (clarithromycin) package insert. North Chicago, IL: AbbVie, Inc.; 2015 Jan.
21. Biaxin® (clarithromycin) package insert. North Chicago, IL: Abbott Laboratories; 2007 March.
22. Gilenya (fingolimod) package insert. East Hanover, New Jersey: Novartis Pharmaceuticals Corporation; Plenaxis (abarelix) package insert. Waltham, MA: Praecis Pharmaceuticals Inc.; 2003 Nov.
23. Uroxatral (alfuzosin) package insert. Cary, NC: Covis Pharmaceuticals, Inc.; 2013 Sep.
24. Amoxapine package insert. Corona, CA: Watson Laboratories, Inc.; 2014 Jun.
25. Apokyn and Apokyn Pen (apomorphine) injection package insert. Durham, NC: Mylan Bertek Pharmaceuticals Inc.; 2010 July.
26. Flexeril (cyclobenzaprine) package insert. Fort Washington, PA: McNeil Consumer Healthcare; 2013 Apr.
27. Trisenox (arsenic trioxide) package insert. Frazer, PA: Cephalon, Inc; 2010 Jun.
28. Coartem (artemether; lumefantrine) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2013 Apr.
29. Saphris (asenapine) package insert. Whitehouse Station, NJ: Schering-Plough Corporation; 2014 Nov.
30. Zithromax (azithromycin 250 mg and 500 mg tablets and azithromycin oral suspension) package insert. New York, NY: Pfizer Inc.; 2014 Mar.
31. Zithromax (azithromycin inj) package insert. New York, NY: Pfizer Inc.; 2014 Mar.
32. Sirturo (bedaquiline) tablet package insert. Titusville, NJ: Janssen Therapeutics; 2014 Oct.
33. Xopenex (levalbuterol) package insert. Marlborough, MA: Sepracor Inc.; 2009 Feb.
34. Ventolin HFA (albuterol sulfate) Inhalation Aerosol package insert. Research Triangle Park, NC: GlaxoSmithKline; 2008 Mar.
35. Foradil inhalation powder (formoterol fumarate) package insert. Kenilworth, NJ: Schering Corporation; 2012 Nov.
36. Demaziere J, Fourcade JM, Busseuil CT, et al. The hazards of chloroquine self prescription in west Africa. J Toxicol Clin Toxicol 1995;33:369-70.
37. Mansfield RJ, Thomas RD. Recurrent syncope. Drug induced long QT syndrome. Postgrad Med J 2001;77:344, 352-3.
38. Pinski SL, Eguia LE, Trohman RG. What is the minimal pacing rate that prevents torsades de pointes? Insights from patients with permanent pacemakers. Pacing Clin Electrophysiol 2002;25:1612-5.
39. Nora Goldschlager, Andrew E Epstein, Blair P Grubb, et al. Etiologic considerations in the patient with syncope and an apparently normal heart. Arch Intern Med 2003;163:151-62.
40. Bryant SG, Guernsey BG, Ingrim NB. Review of bupropion. Clin Pharm 1983;2:525-37.
41. Chlorpromazine package insert. Princeton, NJ: Sandoz Inc; 2010 Sept.
42. Floxin (ofloxacin tablets) package insert. Raritan, NJ: Ortho-McNeal Pharmaceuticals; 2011 Jan.
43. Cipro (ciprofloxacin tablet; suspension) package insert. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc.; 2013 July.
44. Celexa (citalopram) package insert. St. Louis, MO: Forest Pharmaceuticals, Inc.; 2014 Jul.
45. Clozaril (clozapine) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2014 Dec.
46. Degarelix for injection package insert. Suffern, NY: Ferring Pharmaceuticals Inc.; 2008 Dec.
47. FDA Drug Safety Communication: Abnormal heart rhythms associated with use of Anzemet (dolasetron mesylate). Retrieved December 17, 2010. Available on the World Wide Web at: http://www.fda.gov/Drugs/DrugSafety/ucm237081.htm.– LinkOpens in New Tab
48. Richards JR, Schneir AB. Droperidol in the emergency department: is it safe? J Emerg Med 2003;24:441-7.
49. Kao LW, Kirk MA, Evers SJ, et al. Droperidol, QT prolongation, and sudden death: what is the evidence? Ann Emerg Med 2003;41:546-58.
50. Inapsine (Droperidol) Injection package insert. Lake Forest, IL: Akorn, Inc.; 2011 Oct.
51. Inapsine (droperidol) package insert. Lake Forest, IL: Akorn, Inc.; 2011 Nov.
52. Halaven (eribulin mesylate) injection package insert. Woodcliffe Lake, NJ: Eisai Inc.; 2014 Aug.
53. Lexapro (escitalopram) package insert. St. Louis, MO: Forest Pharmaceuticals, Inc.; 2014 Oct.
54. Potiga (ezogabine) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2013 Sept.
55. Flecainide package insert. Pomona, NY: Barr Laboratories, Inc.; 2006 Oct.
56. Factive (gemifloxacin mesylate) package insert. Toronto, ON: Merus Labs International, Inc.; 2013 Aug.
57. Kytril injection (granisetron) package insert. Nutley, NJ: Roche Pharmaceuticals; 2011 Nov.
58. Schmeling WT, Warltier DC, McDonald DJ, et al. Prolongation of the QT interval by enflurane, isoflurane, and halothane in humans. Anesth Analg 1991;72:137-44.
59. Loeckinger A, Kleinsasser A, Maier S, et al. Sustained prolongation of the QTc interval after anesthesia with sevoflurane in infants during the first 6 months of life. Anesthesiology 2003;98:639-42.
60. Kleinsasser A, Loeckinger A, Lindner KH, et al. Reversing sevoflurane-associated Q-Tc prolongation by changing to propofol. Anaesthesia 2001;56:248-50.
61. Kuenszberg E, Loeckinger A, Kleinsasser A, et al. Sevoflurane progressively prolongs the QT interval in unpremedicated female adults. Eur J Anaesthesiol 2000;17:662-4.
62. Haldol injection for immediate release (haloperidol) package insert. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc.; 2011 Sept.
63. Fanapt (iloperidone) package insert. Rockville, MD: Vanda Pharmaceuticals, Inc.; 2014 Apr.
64. Levaquin (levofloxacin) package insert. Titusville, NJ: Janssen Pharmaceutical, Inc.; 2014 Jun.
65. Ludiomil (maprotiline hydrochloride) package insert. Summit, NJ: Ciba-Geigy Corporation; 1996 Nov.
66. Mefloquine package insert. Princeton, NJ: Sandoz Inc.; 2013 Jul.
67. Krantz MJ, Kutinsky IB, Robertson AD, et al. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy 2003;23:802-5.
68. Walker PW, Klein D, Kasza L. High dose methadone and ventricular arrhythmias: a report of three cases. Pain 2003;103:321-4.
69. Kornick CA, Kilborn MJ, Santiago-Palma J, et al. QTc interval prolongation associated with intravenous methadone. Pain 2003;105:499-506.
70. Gil M, Sala M, Anguera I, et al. QT prolongation and Torsades de Pointes in patients infected with human immunodeficiency virus and treated with methadone. Am J Cardiol 2003;92:995-7.
71. Dolophine (methadone) package insert. Columbus, OH: Roxane Laboratories, Inc; 2014 Apr.
72. Avelox (moxifloxacin) package insert. Whitehouse Station, NJ: Merck and Co., Inc.; 2014 Nov.
73. Noroxin (norfloxacin) package insert. Whitehouse Station, NJ: Merck and Co., Inc.; 2013 Jul.
74. Sandostatin (octreotide) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2010 Jan.
75. Zyprexa (olanzapine, all formulations) package insert. Indianapolis, IN: Eli Lilly and Company; 2013 Jul.
76. Zofran (ondansetron injection) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2014 Sep.
77. Invega Sustenna (paliperidone palmitate injectable suspension) package insert. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2014 Nov.
78. Signifor (pasireotide diaspartate) package insert. Stein, Switzerland: Novartis Pharma Stein AG; 2012 Dec.
79. Green PT, Reents S, Harman E, et al. Pentamidine-induced torsades de pointes in a renal tranplant recipient with Pneumocystis carinii pneumonia. S Med J 1990;83:481-4.
80. Wharton JM, Demopulos PA, Goldschlager N. Torsade de pointes during administration of pentamidine isethionate. Am J Med 1987;83:571-6.
81. Owens RC Jr. Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes. Pharmacotherapy 2001;21:301-19.
82. Pentam 300 (pentamidine isethionate) injection package insert. Schaumburg, IL: APP Pharmaceuticals, LLC; 2008 Mar.
83. Definity (perflutren lipid microspheres) package insert. North Billerica, MA: Bristol Myers Squibb Medical Imaging, Inc.; 2011 Oct.
84. Nora Goldschlager, Andrew E Epstein, Blair P Grubb, et al. Etiologic considerations in the patient with syncope and an apparently normal heart. Arch Intern Med 2003;163:151-62.
85. Rythmol SR (propafenone hydrochloride) capsule extended release package insert. Research Triangle Park, NC: GlaxoSmithKline; 2014 Apr.
86. Seroquel (quetiapine fumarate) package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2013 Oct.
87. Gajwani P, Pozuelo L, Tesar G, et al. QT interval prolongation associated with quetiapine (seroquel) overdose. Psychosomatics 2000;41:63-5.
88. Beelen AP, Yeo KTJ, Lewis LD. Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone. Hum Exp Toxicol 2001;20:215-9.
89. Furst BA, Champion KM, Pierre JM, et al. Possible association of QTc interval prolongation with co-administration of quetiapine and lovastatin. Biol Psychiatry 2002;51:264-5.
90. Dextromethorphan; quinidine (Nuedexta) package insert. Aliso Viejo, CA: Avanir Pharmaceuticals, Inc.; 2011 Aug.
91. Lexiscan (regadenoson) package insert. Northbrook, Il: Astellas Pharma; 2014 Sept.
92. Edurant (rilpivirine) package insert. Titusville, NJ: Janssen Therapeutics; 2014 May.
93. Risperdal (risperidone) package insert. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2014 Apr.
94. Istodax (romidepsin) package insert. Bedford, OH: Ben Venue Laboratories, Inc.; Oct 2014.
95. Vesicare (solifenacin) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2012 Jul.
96. Nexavar (sorafenib) package insert. Wayne, NJ; Bayer HealthCare Pharmaceuticals Inc.; 2013 Nov.
97. Sunitinib (Sutent) package insert. New York, NY: Pfizer Labs; 2014 Dec.
98. Prograf (tacrolimus) package insert. Northbrook, IL: Astellas Pharma US, Inc.; 2013 Aug.
99. Vibativ (telavancin) package insert. South San Francisco, CA: Theravance, Inc; 2014 Apr.
100. Xenazine® (tetrabenazine) package insert. Washington, DC: Prestwick Pharmaceuticals; 2008 May.
101. Detrol (tolterodine tartrate) package insert. NY, NY: Pharmacia & Upjohn Co., division of Pfizer; 2011 Feb.
102. Fareston (toremifene citrate) tablets package insert. Espoo, Finland: Orion Pharmaceuticals; 2011 Mar.
103. Oleptro (trazodone hydrochloride) extended-release tablets package insert. Dublin, Ireland: Labopharm Europe Limited; 2014 Jul.
104. Vandetanib (vandetanib) package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2014 March.
105. Zelboraf (vemurafenib tablet) package insert. South San Francisco, CA: Genentech USA, Inc.; 2014 Nov.
106. Effexor® XR (venlafaxine extended-release) package insert. Philadelphia, PA; Wyeth Pharmaceuticals, Inc.; 2008 Jan.
107. Vorinostat (Zolinza) package insert. Whitehouse Station, NJ: Merck & Co., Inc.; 2013 Apr.
108. Bristow MR, Thompson PD, Martin RP, et al. Early anthracycline cardiotoxicity. Am J Med 1978;65:823-32.
109. Hismanal (astemizole) package insert. Titusville, NJ: Janssen Pharmaceutica; 1998 Nov. NOTE: Astemizole was removed voluntarily from the US market in response to safety concerns in 1999.
110. Vascor® (bepridil) package insert. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc.; 2000 Mar.
111. Bretylol® (bretylium) package insert. Manati, Puerto Rico: Du pont Pharmaceuticals; 1991 Jan.
112. Propulsid (cisapride) package insert. Titusville, NJ: Janssen Pharmaceutica; 2006 Oct.
113. Tikosyn (dofetilide) package insert. New York, NY: Pfizer Labs; 2011 Feb
114. Multaq (dronedarone) package insert. Bridgewater, NJ: Sanofi-aventis; 2014 Mar.
115. Raxar (grepafloxacin) package insert. Research Triangle Park, NC: Glaxo Wellcome Inc.; 1997 Nov. NOTE: Grepafloxacin was removed voluntarily from the US market in response to safety concerns in 1999.
116. Halfan® (halofantrine) package insert. Philadelphia, PA: Smith Kline Beecham Pharmaceuticals; 2001 Oct.
117. Orlaam® (levomethadyl) package insert. Columbus, OH: Roxane Laboratories,Inc.; 2000 Jan. NOTE: In August 2003, levomethadyl was voluntarily removed from the US market due to cited reasons such as decreasing sales, safety concerns and the availability of other options for the management of opiate dependance.
118. Serentil® (mesoridazine) package insert. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2001 March.
119. Orap (pimozide) package insert. Sellersville, PA: Teva Pharmaceuticals USA; 2011 Nov.
120. Nora Goldschlager, Andrew E Epstein, Blair P Grubb, et al. Etiologic considerations in the patient with syncope and an apparently normal heart. Arch Intern Med 2003;163:151—62.
121. Zagam (sparfloxacin) package insert. Research Triangle Park, NC: Bertek Pharmaceuticals; 2003 Feb.
122. Monahan BP, Ferguson CL, Killeavy ES et al. Torsades de pointes occurring in association with terfenadine use. JAMA 1990;264:2788—90.
123. Pratt CM et al. Risk of developing life-threatening ventricular arrhythmia associated with terfenadine in comparison with over-the-counter antihistamines, ibuprofen and clemastine. Am J Cardiol 1984;73:346—52.
124. Thioridazine package insert. Philadelphia, PA:Mutual Pharmaceutical Company, Inc;2010 Sept.
125. Geodon® (ziprasidone) package insert. New York, NY: Pfizer: 2013 Jul.
126. Xalkori (crizotinib) package insert. New York, NY: Pfizer Labs; 2014 May.
127. Sprycel (dasatinib) package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2014 April.
128. Tykerb (lapatinib) tablet package insert. Research Triangle Park, NC: GlaxoSmithKline; 2014 December.
129. Korlym (mifepristone) tablet package insert. Menlo Park, CA: Corcept Therapeutics Incorporated; 2013 Jun.
130. Tasigna® (nilotinib) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2007 Oct.
131. Votrient (pazopanib) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2011 Oct.
132. Ranexa (ranolazine extended-release tablets) package insert. Foster City, CA: Gilead Sciences, Inc. 2013 Dec.
133. Ketek (telithromycin) package insert. Bridgewater, NJ: Sanofi-Aventis Pharmaceuticals; 2010 Dec.
134. VFEND (voriconazole) tablets, suspension, and injection package insert. New York, NY: Pfizer Inc; 2015 Feb.
135. 28226
136. Yamreudeewong W, DeBisschop M, Martin LG, et al. Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf 2003;26:421-38.
137. Invirase (saquinavir) package insert. South San Francisco, CA: Genentech Inc.; 2012 Nov.
138. Posaconazole (Noxafil) package insert. Whitehouse Station, NJ: Merck & Co. Inc.: 2014 Jun.
139. Intelence (etravirine) package insert. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2014 Aug.
140. Atazanavir (Reyataz™) package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2008 Sep.
141. Prezista™ (darunavir) package insert. Raritan, NJ: Tibotec Therapeutics; 2008 Feb.
142. Crixivan® (indinavir) package insert. Whitehouse Station, NJ: Merck & Co., Inc.; 2008 Oct.
143. Viracept (nelfinavir mesylate) package insert. Research Triangle Park, NC: ViiV Healthcare Company; 2013 May.
144. Aptivus® (tipranavir) package insert. Ridgefield, CT: Boehringer Ingelheim; 2008 Jun.
145. Sustiva (efavirenz) package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2014 May.
146. Hansten P, Horn J. The Top 100 Drug Interactions: A Guide to Patient Management. includes table of CYP450 and drug transporter substrates and modifiers (appendices). H & H Publications, LLP 2014 edition.
147. Nizoral (ketoconazole tablet) package insert. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2014 Feb.
148. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism. Clin Pharmacokinet 2000;38:111-180.
149. Sporanox (itraconazole) oral solution package insert. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2014 Jun.
150. Bruggemann RJM, Afllenaar JWC, Blijlevens NMA, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009;48:1441-58.
151. Zhang S, Pillai VC, Mada SR, et al. Effect of voriconazole and other azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomes. Xenobiotica 2012;42:409-16.
152. Niwa T, Shiraga T, Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull. 2005;28:1805-1808.
153. Vaprisol® (conivaptan hydrochloride injection). Deerfield, IL: Astellas Pharma US, Inc.; 2007 Feb.
154. Food and Drug Administration Press Office. Roche Laboratories Announces Withdrawal of Posicor® (mibefradil) From the Market. (includes a partial list of drugs that taken in combination with Posicor(R) could be dangerous). FDA Talk Paper. June 8, 1998. Acc
155. Yamreudeewong W, DeBisschop M, Martin LG, et al. Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf 2003;26:421—38.
156. Zyflo™ Filmtab® (zileuton) package insert. Chicago, IL: Abbott Laboratories; 1998 Mar.
157. Tracleer® (bosentan) package insert. South San Francisco, CA: Actelion Pharmaceuticals US, Inc.; 2007 Feb.
158. Cerebyx® (fosphenytoin sodium) package insert. New York, NY: Parke-Davis; 2002 Jun.
159. Priftin® (rifapentine) package insert. Kansas City, MO: Aventis Pharmaceuticals Inc.; 2003 Feb.
160. Rezulin® (troglitazone) package insert. Morris Plains, NJ: Parke-Davis; 1999 June. NOTE: Troglitazone was removed from the US market in response to FDA concerns in March 2000.
161. Dahan A, Altman H. Food-drug interaction: grapefruit juice augments drug bioavailability-mechanism, extent, and relevance. Eur J Clin Nutr 2004;58:1—9.
162. Adalat CC (nifedipine extended-release tablets) package insert. West Haven, CT: Bayer Pharmaceuticals Corporation; 2010 Aug.
163. Kuvan (sapropterin) package insert. Novato, CA: BioMarin Pharmaceutical Inc; 2014 April.
164. Pomeranz HD, Bhavsar AR. Nonarteritic ischemic optic neuropathy developing soon after use of sildenafil (Viagra): a report of seven new cases. J Neuroophthalmol 2005;25:9-13.
165. Escaravage GK Jr, Wright JD Jr, Givre SJ. Tadalafil associated with anterior ischemic optic neuropathy. Arch Ophthalmol 2005;123(3):399-400.
166. Bollinger K, Lee MS. Recurrent visual field defect and ischemic optic neuropathy associated with tadalafil rechallenge. Arch Ophthalmol 2005;123(3):400-1.
167. Peter NM, Singh MV, Fox PD. Tadalafil-associated anterior ischaemic optic neuropathy. Eye 2005;19(6):715-7.